AstraZeneca-Icosavax deal may prompt queries from US FTC, but strong rivals, distinct customers could temper concerns
Both AstraZeneca and clinical-stage vaccine developer Icosavax offer an immunization for respiratory syncytial virus in their drug portfolio – a similarity that may prompt scrutiny from the US Federal Trade Commission...To view the full article, register now.
Already a subscriber? Click here to view full article